Skip to content
2000
Volume 14, Issue 1
  • ISSN: 1871-529X
  • E-ISSN: 2212-4063

Abstract

Stroke is the most feared complication of atrial fibrillation but for over fifty years there has been no simple, effective preventative alternative to warfarin. The development of new risk algorithms such as CHADSVASC has resulted in more patients being recommended anticoagulation therapy. Fixed dose oral anticoagulation is a landmark in drug development for atrial fibrillation. The differences between the drugs are discussed and the trial data examined. As we enter this new frontier of therapy, there is no doubt that these drugs will transform the delivery of anticoagulation for patients with atrial fibrillation.

Loading

Article metrics loading...

/content/journals/chddt/10.2174/1871529X1401140724094846
2014-03-01
2025-06-28
Loading full text...

Full text loading...

/content/journals/chddt/10.2174/1871529X1401140724094846
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test